We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Nasally-Introduced Peptide Could Be New Approach to Preventing SARS-CoV-2 Infection and Treating COVID-19

By HospiMedica International staff writers
Posted on 19 Jan 2021
Print article
Illustration
Illustration
A new potential therapy for COVID-19 being developed by researchers has shown success in preventing the disease’s symptoms in mice.

In a study, mouse models with COVID-19 showed positive results when a peptide (chain of amino acids) designed by researchers at the Rush University Medical Center (Chicago, IL, USA) was introduced nasally. The peptide proved effective in reducing fever, protecting the lungs, improving heart function and reversing cytokine storm - the immune system overreacting to an infection and flooding the bloodstream with inflammatory proteins. The researchers have also reported success in preventing the disease from progression.

Many patients with COVID-19 in intensive care units suffer from cytokine storm, which affects lungs, heart and other organs. Although anti-inflammatory therapies such as steroids are available to treat the problem, very often these treatments cause suppression of the immune system. Despite vaccines for COVID-19 now becoming available, a specific medicine for reducing inflammatory events and treating respiratory and cardiac problems caused by COVID-19 will be necessary for better management of the disease even in the post-vaccine era.

SARS-CoV-2, the virus that causes COVID-19, binds to an enzyme called ACE2 to enter and infect human cells. In response, the research team designed a hexapeptide (a peptide with six amino acids) that inhibits the virus from binding with ACE2.

“The peptide inhibits cytokines that only are produced by the SARS-CoV-2 spike protein, not other inflammatory stimuli, indicating that this peptide would not cause immunosuppression,” said Kalipada Pahan, PhD, the Floyd A. Davis Professor of Neurology at the Rush University Medical Center and a research career scientist at the Jesse Brown VA Medical Center, who led the study. “The peptide inhibits cytokines that only are produced by the SARS-CoV-2 spike protein, not other inflammatory stimuli, indicating that this peptide would not cause immunosuppression.”

“If our peptide results can be replicated in COVID-19 patients, it would be a remarkable advance in controlling this devastating pandemic,” added Pahan. “This could be a new approach to prevent SARS-CoV-2 infection and protect COVID-19 patients from breathing problems and cardiac issues.”

Related Links:
Rush University Medical Center

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Needlefree Closed System Transfer Device
ChemoClave

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.